MétaCan
Menu
Back to cohort
Record W2137527705 · doi:10.1186/alzrt90

Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies

2011· article· en· W2137527705 on OpenAlexaff
Diana W. Shineman, Guriqbal S. Basi, Jennifer L. Bizon, Carol A. Colton, Barry Greenberg, Beth Hollister, John Lincecum, Gabrielle G. Leblanc, Linda H Lee, Feng Luo, Dave Morgan, Iva Morse, Lorenzo M. Refolo, David Riddell, Kimberly Scearce‐Levie, Patrick Sweeney, Juha Yrjänheikki, Howard Fillit

Bibliographic record

VenueAlzheimer s Research & Therapy · 2011
Typearticle
Languageen
FieldComputer Science
TopicComputational Drug Discovery Methods
Canadian institutionsUniversity Health Network
FundersNational Institute on AgingAlzheimer's Drug Discovery Foundation
KeywordsMedicineDiseaseClinical trialTranslational researchAnimal testingClinical study designRegulatory sciencePreclinical researchAnimal modelDrug developmentDrug discoveryBioinformaticsDrugPathologyPharmacologyMedical physicsBiologyInternal medicine

Abstract

fetched live from OpenAlex

Animal models have contributed significantly to our understanding of the underlying biological mechanisms of Alzheimer's disease (AD). As a result, over 300 interventions have been investigated and reported to mitigate pathological phenotypes or improve behavior in AD animal models or both. To date, however, very few of these findings have resulted in target validation in humans or successful translation to disease-modifying therapies. Challenges in translating preclinical studies to clinical trials include the inability of animal models to recapitulate the human disease, variations in breeding and colony maintenance, lack of standards in design, conduct and analysis of animal trials, and publication bias due to under-reporting of negative results in the scientific literature. The quality of animal model research on novel therapeutics can be improved by bringing the rigor of human clinical trials to animal studies. Research communities in several disease areas have developed recommendations for the conduct and reporting of preclinical studies in order to increase their validity, reproducibility, and predictive value. To address these issues in the AD community, the Alzheimer's Drug Discovery Foundation partnered with Charles River Discovery Services (Morrisville, NC, USA) and Cerebricon Ltd. (Kuopio, Finland) to convene an expert advisory panel of academic, industry, and government scientists to make recommendations on best practices for animal studies testing investigational AD therapies. The panel produced recommendations regarding the measurement, analysis, and reporting of relevant AD targets, th choice of animal model, quality control measures for breeding and colony maintenance, and preclinical animal study design. Major considerations to incorporate into preclinical study design include a priori hypotheses, pharmacokinetics-pharmacodynamics studies prior to proof-of-concept testing, biomarker measurements, sample size determination, and power analysis. The panel also recommended distinguishing between pilot 'exploratory' animal studies and more extensive 'therapeutic' studies to guide interpretation. Finally, the panel proposed infrastructure and resource development, such as the establishment of a public data repository in which both positive animal studies and negative ones could be reported. By promoting best practices, these recommendations can improve the methodological quality and predictive value of AD animal studies and make the translation to human clinical trials more efficient and reliable.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.502
metaresearch head score (Gemma)0.423
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Methods · Consensus signal: none
Teacher disagreement score0.502
Threshold uncertainty score0.614

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.5020.423
Meta-epidemiology (narrow)0.0040.003
Meta-epidemiology (broad)0.0080.006
Bibliometrics0.0100.009
Science and technology studies0.0030.020
Scholarly communication0.0200.019
Open science0.0160.010
Research integrity0.0150.039
Insufficient payload (model declined to judge)0.0030.005

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.723
GPT teacher head0.566
Teacher spread0.157 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designNot applicable
Domainnot available
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations135
Published2011
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s Research & TherapySame topicComputational Drug Discovery MethodsFrench-language works237,207